-

12:31:37 PM

RGLS Stock News

RGLS - Regulus Therapeutics Inc

05/17/22 4:30 PM

Nasdaq : RGLS

conferences

Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : RGLS

earnings

Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company

RHEA-AI

positive

05/11/22 8:00 AM

Nasdaq : RGLS

Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or

RHEA-AI

neutral

05/05/22 4:05 PM

Nasdaq : RGLS

earnings

Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its first quarter 2022 financial

RHEA-AI

neutral

03/24/22 8:00 AM

Nasdaq : RGLS

clinical trial

Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today

RHEA-AI

neutral

03/10/22 4:05 PM

Nasdaq : RGLS

earnings

Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced its financial results for the fourth quarter and year

RHEA-AI

neutral

03/03/22 5:15 PM

Nasdaq : RGLS

earnings

Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has scheduled its fourth quarter and year-end

RHEA-AI

neutral

02/24/22 8:00 AM

Nasdaq : RGLS

clinical trial

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of enrollment in the Phase 2 HERA clinical

RHEA-AI

positive

02/10/22 4:30 PM

Nasdaq : RGLS

conferences

Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of

RHEA-AI

neutral

01/20/22 5:18 PM

Nasdaq : RGLS

Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company has completed a pre-investigational new

RHEA-AI

positive

1 2 3 4 5 6 Next

RGLS Data

IndustryPharmaceutical Preparation Manufacturing
Websiteregulusrx.com
CeoJoseph Hagan
Security nameRegulus Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees24
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address10628 Science Center Dr Ste 225
StateCalifornia
CitySan Diego
Zip92121-1124
CountryUS
Phone18582026300

About Regulus Therapeutics Inc

Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA.